News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Subscribe To Our Newsletter & Stay Updated
